破解2025年初波兰前所未有的流感激增:病毒严重程度增加还是大流行后的脆弱性?

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Piotr Rzymski, Anna Piekarska, Robert Pleśniak, Dominik Sznajder, Dorota Zarębska-Michaluk, Krzysztof Tomasiewicz, Maciej Piasecki, Monika Pazgan-Simon, Justyna Hlebowicz, Karolina Turzańska, Włodzimierz Mazur, Paweł Skwara, Katarzyna Sikorska, Piotr Czupryna, Szymon Piaszczyński, Robert Flisiak
{"title":"破解2025年初波兰前所未有的流感激增:病毒严重程度增加还是大流行后的脆弱性?","authors":"Piotr Rzymski, Anna Piekarska, Robert Pleśniak, Dominik Sznajder, Dorota Zarębska-Michaluk, Krzysztof Tomasiewicz, Maciej Piasecki, Monika Pazgan-Simon, Justyna Hlebowicz, Karolina Turzańska, Włodzimierz Mazur, Paweł Skwara, Katarzyna Sikorska, Piotr Czupryna, Szymon Piaszczyński, Robert Flisiak","doi":"10.1007/s43440-025-00731-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>At the end of 2024, Polish infectious disease specialists observed a sharp increase in influenza hospitalizations, raising concerns about potential underlying causes. This study aimed to analyze differences in patient characteristics, disease progression, and outcomes among individuals hospitalized for influenza in January 2025 compared to January 2024.</p><p><strong>Methods: </strong>We conducted an exploratory retrospective comparative study across leading infectious disease units in Poland, evaluating demographic data, clinical presentations, treatment regimens, and outcomes of hospitalized influenza patients from both periods. Key variables included influenza type, age, sex distribution, symptom profile, oxygen saturation, inflammatory markers, presence of co-infections, and type of treatment.</p><p><strong>Results: </strong>Hospitalizations surged by 630% in January 2025, with in-hospital mortality nearly quadrupling to 10.7%. Despite this, patients from both periods had comparable demographic and clinical admission profiles. Most were treated with oseltamivir (though its use was below 90%), and most required antibiotics for bacterial co-infections. Unsurprisingly, the vast majority of hospitalized patients (97%) and non-survivors (93%) in 2025 were unvaccinated. Among non-survivors in 2025, all were infected with influenza A, were older, had higher rates of chronic peripheral circulatory failure, chronic kidney disease, and immunodeficiency, and exhibited more severe inflammatory responses, lower oxygen saturation, and a higher prevalence of dyspnea.</p><p><strong>Conclusion: </strong>The observed surge likely reflects a post-pandemic phenomenon in a vulnerable, aging, comorbid, and largely unvaccinated population. The findings highlight the urgent need for enhanced influenza vaccination strategies in high-risk groups in Poland, as well as the importance of maintaining continuous antiviral availability throughout the epidemic season. Further research encompassing full-season comparisons and incorporating virological, immunological, and health system factors are warranted to better understand the drivers of such surges and guide future preparedness efforts.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unraveling Poland's unprecedented influenza surge in early 2025: increased viral severity or post-pandemic vulnerability?\",\"authors\":\"Piotr Rzymski, Anna Piekarska, Robert Pleśniak, Dominik Sznajder, Dorota Zarębska-Michaluk, Krzysztof Tomasiewicz, Maciej Piasecki, Monika Pazgan-Simon, Justyna Hlebowicz, Karolina Turzańska, Włodzimierz Mazur, Paweł Skwara, Katarzyna Sikorska, Piotr Czupryna, Szymon Piaszczyński, Robert Flisiak\",\"doi\":\"10.1007/s43440-025-00731-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>At the end of 2024, Polish infectious disease specialists observed a sharp increase in influenza hospitalizations, raising concerns about potential underlying causes. This study aimed to analyze differences in patient characteristics, disease progression, and outcomes among individuals hospitalized for influenza in January 2025 compared to January 2024.</p><p><strong>Methods: </strong>We conducted an exploratory retrospective comparative study across leading infectious disease units in Poland, evaluating demographic data, clinical presentations, treatment regimens, and outcomes of hospitalized influenza patients from both periods. Key variables included influenza type, age, sex distribution, symptom profile, oxygen saturation, inflammatory markers, presence of co-infections, and type of treatment.</p><p><strong>Results: </strong>Hospitalizations surged by 630% in January 2025, with in-hospital mortality nearly quadrupling to 10.7%. Despite this, patients from both periods had comparable demographic and clinical admission profiles. Most were treated with oseltamivir (though its use was below 90%), and most required antibiotics for bacterial co-infections. Unsurprisingly, the vast majority of hospitalized patients (97%) and non-survivors (93%) in 2025 were unvaccinated. Among non-survivors in 2025, all were infected with influenza A, were older, had higher rates of chronic peripheral circulatory failure, chronic kidney disease, and immunodeficiency, and exhibited more severe inflammatory responses, lower oxygen saturation, and a higher prevalence of dyspnea.</p><p><strong>Conclusion: </strong>The observed surge likely reflects a post-pandemic phenomenon in a vulnerable, aging, comorbid, and largely unvaccinated population. The findings highlight the urgent need for enhanced influenza vaccination strategies in high-risk groups in Poland, as well as the importance of maintaining continuous antiviral availability throughout the epidemic season. Further research encompassing full-season comparisons and incorporating virological, immunological, and health system factors are warranted to better understand the drivers of such surges and guide future preparedness efforts.</p>\",\"PeriodicalId\":19947,\"journal\":{\"name\":\"Pharmacological Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacological Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s43440-025-00731-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43440-025-00731-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在2024年底,波兰传染病专家观察到流感住院人数急剧增加,引起了对潜在原因的担忧。本研究旨在分析2025年1月与2024年1月因流感住院的个体在患者特征、疾病进展和结局方面的差异。方法:我们在波兰主要传染病单位进行了一项探索性回顾性比较研究,评估两个时期住院流感患者的人口统计数据、临床表现、治疗方案和结局。关键变量包括流感类型、年龄、性别分布、症状概况、氧饱和度、炎症标志物、合并感染的存在和治疗类型。结果:2025年1月住院人数激增630%,住院死亡率几乎翻了两番,达到10.7%。尽管如此,这两个时期的患者具有可比性的人口统计学和临床入院资料。大多数人用奥司他韦治疗(尽管使用率低于90%),大多数人需要抗生素治疗细菌合并感染。不出所料,2025年绝大多数住院患者(97%)和非幸存者(93%)未接种疫苗。在2025年的非幸存者中,所有人都感染了甲型流感,年龄较大,慢性外周循环衰竭,慢性肾脏疾病和免疫缺陷的发生率较高,并且表现出更严重的炎症反应,更低的血氧饱和度和更高的呼吸困难患病率。结论:观察到的激增可能反映了大流行后在脆弱、老龄化、合并症和大部分未接种疫苗人群中的现象。研究结果强调了在波兰高危人群中加强流感疫苗接种战略的迫切需要,以及在整个流行季节保持持续获得抗病毒药物的重要性。有必要进行包括全季节比较和纳入病毒学、免疫学和卫生系统因素的进一步研究,以更好地了解这种激增的驱动因素并指导未来的防范工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unraveling Poland's unprecedented influenza surge in early 2025: increased viral severity or post-pandemic vulnerability?

Background: At the end of 2024, Polish infectious disease specialists observed a sharp increase in influenza hospitalizations, raising concerns about potential underlying causes. This study aimed to analyze differences in patient characteristics, disease progression, and outcomes among individuals hospitalized for influenza in January 2025 compared to January 2024.

Methods: We conducted an exploratory retrospective comparative study across leading infectious disease units in Poland, evaluating demographic data, clinical presentations, treatment regimens, and outcomes of hospitalized influenza patients from both periods. Key variables included influenza type, age, sex distribution, symptom profile, oxygen saturation, inflammatory markers, presence of co-infections, and type of treatment.

Results: Hospitalizations surged by 630% in January 2025, with in-hospital mortality nearly quadrupling to 10.7%. Despite this, patients from both periods had comparable demographic and clinical admission profiles. Most were treated with oseltamivir (though its use was below 90%), and most required antibiotics for bacterial co-infections. Unsurprisingly, the vast majority of hospitalized patients (97%) and non-survivors (93%) in 2025 were unvaccinated. Among non-survivors in 2025, all were infected with influenza A, were older, had higher rates of chronic peripheral circulatory failure, chronic kidney disease, and immunodeficiency, and exhibited more severe inflammatory responses, lower oxygen saturation, and a higher prevalence of dyspnea.

Conclusion: The observed surge likely reflects a post-pandemic phenomenon in a vulnerable, aging, comorbid, and largely unvaccinated population. The findings highlight the urgent need for enhanced influenza vaccination strategies in high-risk groups in Poland, as well as the importance of maintaining continuous antiviral availability throughout the epidemic season. Further research encompassing full-season comparisons and incorporating virological, immunological, and health system factors are warranted to better understand the drivers of such surges and guide future preparedness efforts.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmacological Reports
Pharmacological Reports 医学-药学
CiteScore
8.40
自引率
0.00%
发文量
91
审稿时长
6 months
期刊介绍: Pharmacological Reports publishes articles concerning all aspects of pharmacology, dealing with the action of drugs at a cellular and molecular level, and papers on the relationship between molecular structure and biological activity as well as reports on compounds with well-defined chemical structures. Pharmacological Reports is an open forum to disseminate recent developments in: pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology. Studies of plant extracts are not suitable for Pharmacological Reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信